Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 16/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18812267 | 0.92 | GRK2 (0.36) | GRK2ROCK2MAPT | |
| SCHEMBL16475038 | 0.90 | GRK2 (0.37) | GRK2ROCK2 | |
| SCHEMBL18077782 | 0.86 | CHUK (0.35) | GRK2ROCK2MAPT | |
| SCHEMBL18812103 | 0.85 | PRKACA (0.35) | MAPTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18077761 | 0.85 | AXL (0.36) | MAPTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16475015 | 0.82 | GRM5 (0.37) | GRK2ROCK2 | |
| SCHEMBL18811825 | 0.81 | ROCK2 (0.34) | GRK2ROCK2MAPT | |
| SCHEMBL18077781 | 0.79 | ROCK2 (0.33) | GRK2ROCK2MAPT | |
| SCHEMBL18077779 | 0.79 | MAT2A (0.37) | ROCK2MAPT | |
| SCHEMBL17803746 | 0.78 | GRM5 (0.38) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | GRK2 2893/4885ROCK2 1113/4885MAPT 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.